Expanding Options for Patients The landscape for treating prostate cancer has reached a significant turning point. The FDA has officially approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC). Understanding the Treatment Pluvicto is a targeted radioligand therapy. This means it…